The European Medicines Agency has temporarily suspended enrollment and dosing in a Phase II trial of Sarepta Therapeutics' ...

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

CNS specialist Axsome Therapeutics has announced results from the PARADIGM Phase III proof-of-concept trial of solriamfetol ...

A biotech company advancing next-generation targeted protein degradation (TPD) therapies for intractable diseases.

Swiss clinical-stage biotech AC Immune’s (Nasdaq: ACIU) shares closed up 5.9% at $1.90 yesterday, after it announced additional interim safety and positive immunogenicity data from the Phase II VacSYn ...

US biotech Artis BioSolutions has officially launched with the acquisition of Landmark Bio, a translational development and ...

Swedish Orphan Biovitrum, the Nordic biotech also known as Sobi, has announced that the National Institute for Health and ...

US biotech Inhibrx Biosciences (Nasdaq: INBX) has announced a leadership shake-up following the departure of co-founder ...

The American Gastroenterological Association (AGA) has recently released a major update to its clinical guideline for the ...

German tech conglomerate Siemens has signed an agreement with Miko Pharma to develop facilities for the local production of ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

Plenty of money changed hands in pharma M&A during March, with the biggest deal a $6.7 billion merger between Mallinckrodt ...